Pfizer's oncology promises are several years from being actualized. Read why investors shouldn't assume that a sustained ...

So when vaccine skeptic Robert F. Kennedy Jr. was offered the top job at the Department of Health and Human Services, Pfizer ...

The Vyndaqel family of drugs for the treatment of transthyretin amyloid cardiomyopathy is Pfizer’s fourth top-selling product ...

Shares of pharmacy benefit managers extended losses Tuesday after Pfizer Inc. Chief Executive Officer Albert Bourla said ...

Pfizer is fending off investors’ fears about threats to its vaccine business under the Trump administration.

Pfizer said Tuesday it does not expect the Trump administration to make major changes to vaccine policy next year even with ...

The push to replace Albert Bourla as Pfizer’s CEO drew attention from the pharma industry but was soon derailed by several ...

President-elect was happy that "he and his program [Operation Warp Speed] contributed significantly," to vaccine development, ...

Pfizer Inc. forecast 2025 sales and earnings in line with analysts’ projections, a step toward fending off an activist ...

Revenue in 2025 will be $61 billion to $64 billion, Pfizer said, in line with predictions by Wall Street analysts.

Pfizer shares rose Tuesday morning after the pharmaceutical company affirmed its full-year 2024 projections and issued 2025 ...